Xtreme Fighting Championships 44 Preliminary Card Airs Live On XFCTV.com Before Main Card Dominates FOX

PR Newswire

DESTIN, Fla., April 29, 2021 /PRNewswire/ — Xtreme Fighting Championships (OTC: DKMR) has unveiled the Preliminary Card for its next action-packed event, XFC 44 on May 28 at Wells Fargo Arena in Des Moines, IA, and also announced that the Preliminary Card will air live on XFCTV.com.

The XFC 44 Preliminary Card features many athletes that XFC fans are excited to see return to the Hexagon, including Luis Navarro, Davi Young, Cody Linne and Datrelle Kozeluh.

XFC 44 Preliminary Card


May 28 | Wells Fargo Arena in Des Moines, IA | XFCTV.com

YoungGuns Bantamweight Bout: Tyrell Hill vs. Darnell White
YoungGuns Welterweight Bout: Luis Navarro vs. Tyson Miller
YoungGuns Lightweight Bout: Davi Young vs. Jake Kozorosky
YoungGuns Flyweight Bout: Cody Linne vs. Datrelle Kozeluh
YoungGuns Featherweight Bout: James Bennett vs. Boston Salmon
YoungGuns Lightweight Bout: Ygor Gorbachev vs. Juan Roman
YoungGuns Flyweight Bout: Atty Belanger vs. Autumn Newcomb

The XFC 44 Main Card, which airs live on FOX Deportes and FOX Sports 2, features the return of Andre “The Asian Sensation” Soukhamthath versus Jose “El Teco” Quinonez in the Main Event, the Semifinal Rounds of the XFC Lightweight and Welterweight Tournaments, and much more.

XFC 44 Main Card


May 28 | Wells Fargo Arena in Des Moines, IA | FOX Deportes/FOX Sports 2

Andre Soukhamthath (14-8) vs. Jose Quinonez (8-5)
Bantamweight Main Event
Kurt Holobaugh (18-7) vs. Scott Hudson (12-5-1)
XFC Lightweight Tournament Semifinal
Tom O’Connor (9-1) vs. Damonte Robinson (6-1-1)
XFC Lightweight Tournament Semifinal
LaRue Burley (10-4) vs. Carson Hardman (9-2)
XFC Welterweight Tournament Semifinal
Ryan Dickson (11-5) vs. Bobby Nash (10-4)
XFC Welterweight Tournament Semifinal
Chris Barnett (21-6) vs. Brett Martin (9-1)
Heavyweight Feature Bout
Austin Bashi (3-0) vs. Emanuel Pugh (pro debut)
Bantamweight Feature Bout

XFC President Myron Molotky: “It’s well established what the XFC is looking for from its YoungGuns division; non-stop action, heart and character. Our matchmakers have done an exceptional job identifying and signing the next generation of MMA superstars, and the future is going to be on full display live on XFCTV.com on May 28.”

XFC CEO Steve Smith: “The Preliminary Card is just as important to us as our Main Event at XFC, and these early bouts could steal the show on our biggest card yet. This very talented line-up of athletes includes many names and faces that combat sports fans around the world are going to be very familiar with for a long time.”

About XFC

Xtreme Fighting Championships, Inc. (formerly Duke Mountain Resources, Inc.) is the first publicly traded premier international mixed martial arts (“MMA”) organization with offices throughout the United States and South America, trading under the ticker symbol DKMR. Xtreme Fighting Championships (“XFC”) is now partnered with the FOX family of networks in the United States, and has previously been carried on some of the largest open television broadcasters in Latin America – Rede TV! as well as HBO, ESPN, NBC Sports Network, Telemundo Universo, Esportes Interativo, Terra TV (the largest internet portal in the world), and UOL – the largest internet portal in Latin America, and premium cable & satellite television network. The XFC has had over 185 exclusively signed fighters, representing over 35+ countries worldwide with even more growth expected. Boasting the signing of The Next Generation of Male & Female Superstars, the XFC is known for entertaining fans with the most action packed MMA events both on television and in stadium venues. The Next Generation of MMA.

Media Contact:
Ed Kapp
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/xtreme-fighting-championships-44-preliminary-card-airs-live-on-xfctvcom-before-main-card-dominates-fox-301279902.html

SOURCE Xtreme Fighting Championships

High Tide Acquires One of the Original Ontario Licensed Cannabis Retail Stores

PR Newswire

CALGARY, AB, April 29, 2021 /PRNewswire/ – High Tide Inc. (“High Tide” or the “Company“) (TSXV: HITI) (OTCQB: HITIF) (FRA: 2LY), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, is pleased to announce that it has completed the acquisition (the “Transaction“) of the Canna Cabana retail cannabis store located at 435(B) Yonge Street in Toronto, Ontario (the “Toronto Store“). The Toronto Store has a strong operating history, being one of the original 25 cannabis retail stores operating in the province. To date, High Tide has earned over $1 million in royalties from the Toronto Store.

In connection with the Transaction, the Company acquired all of the shares of a company owned by the original holder of the cannabis retail store authorization issued by the Alcohol and Gaming Commission of Ontario. High Tide and the vendor agreed to reduce the original purchase price, agreed in March 2019, which was to be partially paid in common shares in the capital of the Company (“HITI Shares“) at a deemed price of $0.48. As consideration for the acquisition, High Tide paid the vendor approximately $4 million in cash, and assumed the company’s loan to open and build the Toronto Store, saving High Tide over $2.3 million1 of dilution and cash.

“As one of the original Ontario lottery winners, the Toronto Store has been successfully operating on Toronto’s iconic Yonge Street since June 2019 and has demonstrated consistent success for almost two years,” said Raj Grover, High Tide’s President & Chief Executive Officer. “We are very pleased to bring this store with its well established track record and existing customer base into our corporately owned portfolio. We remain focused on increasing our retail footprint in Ontario, Canada’s largest cannabis market.” added Mr. Grover.

About High Tide Inc.

High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories. The Company is the most profitable Canadian retailer of recreational cannabis as measured by Adjusted EBIDTA,2 with 85 current locations spanning Ontario, Alberta, Manitoba and Saskatchewan. High Tide’s retail segment features the Canna Cabana, KushBar, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country. High Tide has been serving consumers for over a decade through its numerous consumption accessory businesses including e-commerce platforms Grasscity.com and CBDcity.com, and its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Aphria Inc. (TSX:APHA) (NYSE:APHA) and Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB).

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

______________


1 

Based on the current market price of HITI Shares if the original structure with the vendor was maintained.


2 

Adjusted EBITDA is a non-IFRS financial measure. 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”,  “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to the potential effects of the Transaction on the business of High Tide. While High Tide considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.

Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving the retail cannabis markets; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the retail cannabis industries generally; income tax and regulatory matters; the ability of High Tide to implement its business strategy; competition; currency and interest rate fluctuations; the COVID-19 pandemic nationally and globally and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores and other risks.
Readers are cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Readers are further cautioned that the assumptions used in the preparation of such forward-looking statements (including, but not limited to, the assumption that (i) High Tide’s financial condition and development plans do not change as a result of unforeseen events, (ii) there will continue to be a demand, and market opportunity, for High Tide’s product offerings; (iii) current and future economic conditions will neither affect the business and operations of High Tide nor High Tide’s ability to capitalize on anticipated business opportunities, although considered reasonable by management of High Tide at the time of preparation, may prove to be imprecise and result in actual results differing materially from those anticipated, and as such, undue reliance should not be placed on forward-looking statements.

Forward-looking statements, forward-looking financial information and other metrics presented herein are not intended as guidance or projections for the periods referenced herein or any future periods, and in particular, past performance is not an indicator of future results and the results of High Tide in this press release may not be indicative of, and are not an estimate, forecast or projection of High Tide future results.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. High Tide disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in High Tide’s public filings and material change reports, which are and will be available on SEDAR.


This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/high-tide-acquires-one-of-the-original-ontario-licensed-cannabis-retail-stores-301279781.html

SOURCE High Tide Inc.

Global Net Lease Announces $250 Million Of Closed Acquisitions Year To Date

PR Newswire

NEW YORK, April 29, 2021 /PRNewswire/ — Global Net Lease, Inc. (NYSE: GNL) (“GNL” or the “Company”) announced today that as of April 28, 2021 the Company has closed on five properties for a contract purchase price of $249.8 million1 since the beginning of the year, including the previously announced acquisition of the McLaren Group headquarters in Woking, Surrey, England. The acquisitions were completed at a going-in capitalization rate2 of 9.1% and had a weighted average remaining lease term of 19.4 years at closing.

“We are off to a strong start to 2021 and have already acquired nearly a quarter-billion dollars of high-quality, mainly industrial assets year to date,” said James Nelson, CEO of GNL “The year to date acquisitions, at attractive cap rates and terms, will continue GNL’s growth trajectory and the long weighted-average lease duration of these assets are expected to further enhance our high quality portfolio.”

About Global Net Lease, Inc.
Global Net Lease, Inc. (NYSE: GNL) is a publicly traded real estate investment trust listed on the NYSE focused on acquiring a diversified global portfolio of commercial properties, with an emphasis on sale-leaseback transactions involving single tenant, mission critical income producing net-leased assets across the United States, Western and Northern Europe. Additional information about GNL can be found on its website at www.globalnetlease.com.

Important Notice
The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results or events to be materially different. The words “anticipates,” “believes,” “expects,” “estimates,” “projects,” “plans,” “intends,” “may,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the potential adverse effects of the ongoing global coronavirus pandemic, including actions taken to contain or treat the coronavirus, on the Company, the Company’s tenants and the global economy and financial markets as well as those risks and uncertainties set forth in the Risk Factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed on February 26, 2021, and all other filings with the SEC after that date, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results, unless required to do so by law. 

Contacts:

Investors and Media:
Email: [email protected]
Phone: (212) 415-6510

1.

Based on prevailing exchange rates on date of closing.

2.

Going-in capitalization rate is a rate of return on a real estate investment property based on the expected, cash rental income that the property will generate under its existing lease during the first year of the lease. Going-in capitalization rate is calculated by dividing the cash rental income the property will generate during the first year of the lease (before debt service and depreciation and after fixed costs and variable costs) and the purchase price of the property. The weighted average going-in capitalization rate is based upon square feet of the date of acquisition.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/global-net-lease-announces-250-million-of-closed-acquisitions-year-to-date-301279708.html

SOURCE Global Net Lease, Inc.

Embraer S.A. Releases Its First Quarter 2021 Earnings Results

PR Newswire

SÃO PAULO, April 29, 2021 /PRNewswire/ — EMBRAER S.A. (NYSE: ERJ; B3: EMBR3) releases its First Quarter 2021 Earnings Results.

HIGHLIGHTS

  • Embraer delivered 9 commercial jets and 13 executive jets (10 light / 3 large) in 1Q21. Total company firm order backlog at the end of 1Q21 was US$ 14.2 billion;
  • Revenues in 1Q21 reached US$ 807.3 million, representing year-over-year growth of 27.4% compared to 1Q20, with growth in the Commercial Aviation, Defense & Security, and Executive Aviation segments;
  • On April 23, the Company signed a firm order for 30 E195-E2 jets with an undisclosed customer, with deliveries starting in 2022. The 30 firm orders will be included in Embraer’s second quarter backlog;
  • Excluding special items, adjusted EBIT and EBITDA were US$ (29.6) million and US$ 18.0 million, respectively, yielding adjusted EBIT margin of -3.7% and adjusted EBITDA margin of 2.2%;
  • Adjusted net loss (excluding special items and deferred income tax and social contribution) in 1Q21 was US$ (95.9) million, with adjusted loss per ADS of US$ (0.52);
  • Embraer free cash flow in 1Q21 was a usage of US$ (226.6) million, which is consistent with normal quarterly seasonality of free cash flow usage in the first quarter. The free cash flow usage represented a significant improvement compared to the US$ (676.6) million in free cash flow consumption in 1Q20 on considerably better inventory levels given steps taken to stabilize production and operations in the midst of the COVID-19 pandemic;
  • The Company finished the quarter with total cash of US$ 2.5 billion and net debt of US$ 1.9 billion;
  • Due to continued uncertainty related to the COVID-19 pandemic and its impacts on the industry, Embraer has decided to not publish 2021 financial and delivery guidance at this point.

MAIN FINANCIAL INDICATORS


US$ Million


1Q20


4Q20


1Q21

Revenue

633.8

1,841.4

807.3

EBIT

(46.9)

103.6

(33.1)

EBIT margin %

-7.4%

5.6%

-4.1%

Adjusted EBIT

8.7

76.6

(29.6)

Adjusted EBIT margin %

1.4%

4.2%

-3.7%

EBITDA

9.3

172.6

14.5

EBITDA margin %

1.5%

9.4%

1.8%

Adjusted EBITDA

64.9

145.6

18.0

Adjusted EBITDA margin %

10.2%

7.9%

2.2%

Adjusted net income (Loss)

(104.0)

(12.5)

(95.9)

Adjusted earnings (losses) per share – ADS basic

(0.5651)

(0.0679)

(0.5219)

Net income (loss) attributable to Embraer Shareholders

(292.0)

(3.3)

(89.7)

Earnings (losses) per share – ADS basic (US$)

(1.5867)

(0.0179)

(0.4882)

Adjusted free cash flow

(676.5)

725.1

(226.5)

Net debt

(1,331.6)

(1,695.7)

(1,902.2)

For additional information, please check the full document on our website

ri.embraer.com.br

INVESTOR RELATIONS

Eduardo Couto, Chris Thornsberry, Caio Pinez and Viviane Pinheiro.
(+55 11) 3040-6874
[email protected]
ri.embraer.com.br

CONFERENCE CALL INFORMATION
Embraer will host a conference call to present its 1Q21 Results on Thursday, April 29, 2021 at 11:00 AM (SP) / 10:00 AM (NY). The conference call will also be broadcast live over the web at ri.embraer.com.br

Conference ID: EMBRAER

Telephones USA / Canada: +1 (412) 717-9627 / +1 (844) 204-8942
Telephones Brazil: +55 (11) 4210-1803 / +55 (11) 3181-8565
We recommend calling 15 minutes in advance.

Cision View original content:http://www.prnewswire.com/news-releases/embraer-sa-releases-its-first-quarter-2021-earnings-results-301279649.html

SOURCE Embraer S.A.

Clarivate Reports First Quarter 2021 Results

— Updates 2021 Outlook —

PR Newswire

LONDON, April 29, 2021 /PRNewswire/ — Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a global leader in providing trusted information and insights to accelerate the pace of innovation, today reported results for the first quarter ended March 31, 2021. 

First Quarter 2021 Financial Highlights

  • Revenues of $428.4 million and Adjusted Revenues(1) of $431.5 million, both increased 78%.
  • Organic revenues(1), which exclude the impact of acquisitions and divestitures, increased 8% on a reported basis and 7% on an adjusted basis, at constant currency; organic subscription and transactional revenues(1) increased 6% and 10%, respectively, at constant currency.
  • GAAP Loss from operations of $(34.2) million, an increase of $5.9 million.
  • Adjusted EBITDA(1) of $164.8 million increased 111% and Adjusted EBITDA Margin(1) of 38% increased 600 basis points.
  • Cash Flow from Operations of $174.0 million increased $127.9 million; Adjusted Free Cash Flow(1) of $163.2 million increased $85.3 million.
  • Total cash and cash equivalents of $399.0 million increased $141.3 million.

“Our strong first quarter results reflect the benefits of continued operational improvements and recent acquisitions,” said Jerre Stead, Executive Chairman and CEO. “While the COVID pandemic impacted our business for most of 2020, we are very pleased to see a recovery in organic subscription and transactional revenue growth. With the solid start to the year, we have updated our 2021 financial outlook and continue to see a pathway to achieving 6% to 8% organic revenue growth exiting 2021.” 

Selected Financial Information
(Amounts in tables may not sum due to rounding)

On April 29, 2021, the Company filed a Current Report on Form 8-K noting that following consideration of an April 12, 2021 announcement by the Securities and Exchange Commission that is broadly applicable to warrants issued by special purpose acquisition companies (“SPACs”), the Company concluded that certain of its warrants, originally issued by the SPAC that the Company merged with in 2019, should be classified as liabilities in the Company’s financial statements prepared according to generally accepted accounting principles (“GAAP”). As noted, we are in the process of restating previously issued financial statements, and we are finalizing our financial statements for the quarter ended March 31, 2021, to reflect this change. We anticipate that this change will require certain non-cash adjustments to our financial statements that, among other things, will increase the liabilities carried on our balance sheet by the fair value of these warrants and will require us to assess the fair value of these liabilities each period, with any resulting increase or decrease in fair value recognized in our earnings. We anticipate that this change will not affect GAAP revenues, loss from operations, long-term debt or cash flows from operating activities, or the non-GAAP measures Adjusted EBITDA, Free Cash Flow or Adjusted Free Cash Flow. As a result, in this earnings release we are providing these unaffected measures to illustrate our operational performance for the quarter ended March 31, 2021. We anticipate that this change will affect GAAP benefit (provision) for income taxes, net loss, earnings per share, current liabilities, total liabilities and shareholders’ equity. We do not expect the change to have any significant impact on operational performance or debt covenant compliance in future periods. The affected measures will be addressed in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021. Because we have not yet finalized GAAP net loss for the quarters ended March 31, 2021 or 2020, in this earnings release we provide a reconciliation of non-GAAP Adjusted EBITDA to GAAP loss from operations. Please see “Reconciliations of Certain Non-GAAP Measures.”

The results for the three months ended March 31, 2021 include contributions from CPA Global, which was completed in October 2020, for which there were no comparable amounts in the three months ended March 31, 2020. Additionally, the first quarter ended March 31, 2020 includes only one month of Decision Resources Group (“DRG”) compared to the full quarter ended March 31, 2021, as the acquisition was completed at the end of February 2020. The results for the three months ended March 31, 2021 exclude the results of Techstreet, which was divested in November 2020.


Three Months


Ended March 31,


Change

(in millions, except percentages and per share data)


2021


2020


$


%

Revenues, net

428.4

240.6

187.8

78

%

Adjusted revenues, net(1)

431.5

242.5

189.0

78

%

Annualized Contract Value (ACV)

909.4

820.3

89.1

11

%

Loss from operations

(34.2)

(28.3)

5.9

21

%

Adjusted EBITDA(1)

164.8

78.2

86.6

111

%

Net cash provided by operating activities

174.0

46.1

127.9

N/M

Free cash flow(1)

141.0

26.7

114.3

N/M

Adjusted free cash flow(1)

163.2

77.9

85.3

N/M

(1)

Non-GAAP measure. Please see “Reconciliation to Certain Non-GAAP measures” in this earnings release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this earnings press release.

First Quarter 2021 Operating Results
Revenues, net, for the first quarter of 2021 increased $187.8 million, or 78%, to $428.4 million, compared to the prior-year period. Adjusted revenues, net, which excludes the impact of deferred revenues resulting from purchase accounting adjustments related to acquisitions, increased $189.0 million or 78%, to $431.5 million, compared to the first quarter of 2020. Excluding the impact of acquisitions and divestitures, adjusted organic revenues increased 7% on a constant currency basis, due to higher subscription and transactional revenues.

Subscription revenues for the first quarter of 2021 increased $41.9 million, or 22%, to $235.1 million, compared to the prior-year period, primarily driven by the acquisitions of CPA Global and DRG, partially offset by the Techstreet divestiture. Excluding the impact of acquisitions and divestitures, organic subscription revenues increased $18.5 million, up 6% on a constant currency basis, due to the benefit of net installations in prior-year, timing benefits due to more disciplined operating procedures and price increases.

Re-occurring revenues for the first quarter of 2021 were $112.2 million, an increase of 100%, all driven by acquired revenue primarily from the CPA Global patent renewals business.

Transactional revenues for the first quarter of 2021 increased $34.9 million, or 71%, to $84.2 million, compared to the prior-year period, primarily driven by acquisitions. Excluding the impact of acquisitions and divestitures, organic transactional revenues increased $6.3 million, up 10% on a constant currency basis, compared to the first quarter of 2020. The growth in organic revenues is due to strength in our professional services business lines and an increase in trademark and patent search volumes.

Loss from operations for the first quarter 2021 was $34.2 million, an increase of $5.9 million compared to the prior-year period. Adjusted EBITDA for the first quarter 2021 was $164.8 million, an increase of $86.6 million or 111%, compared to the prior-year period, driven by the earnings contribution from acquisitions and organic growth.

Cash Flow
At March 31, 2021 cash and cash equivalents of $399.0 million increased $141.3 million, compared to December 31, 2020, driven by strong operating results.

The Company’s total debt outstanding at March 31, 2021 was $3,540.3 million, a decrease of $7.2 million compared to December 31, 2020.

Net cash provided by operating activities was $174.0 million for the three months ended March 31, 2021 compared to net cash provided by operating activities of $46.1 million for the prior-year period, driven by strong operating results and tighter working capital management. Adjusted free cash flow for the three months ended March 31, 2021 was $163.2 million, an increase of $85.3 million, compared to the prior-year period, as a result of growth in revenues and operational efficiencies.

Updated Outlook for 2021 (forward-looking statement) 
The full year 2021 updated outlook presented below assumes no further currency movements, acquisitions, divestitures, or unanticipated events. We will provide our Adjusted earnings per share guidance after finalizing the financial statement impacts discussed above and expect to file our Form 10-Q by May 10, 2021.

The below outlook includes Non-GAAP measures. Please see “Reconciliation to Certain Non-GAAP measures” presented below for important disclosure and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this earnings press release.


Updated Outlook


Previous Outlook

Adjusted revenues

$1.79B to $1.84B

$1.78B to $1.84B

Adjusted EBITDA

$790M to $825M

$785M to $825M

Adjusted EBITDA margin

Unchanged

44% to 45%

Adjusted free cash flow

Unchanged

$450M to $500M

Conference Call and Webcast
Clarivate will host a conference call and webcast today to review the results for the first quarter at 8:00 a.m. Eastern Time. The conference call will be simultaneously webcast on the Investor Relations section of the company’s website.

Interested parties may access the live audio broadcast by dialing 1-888-317-6003 in the United States, 1-412-317-6061 for international, and 1-866-284-3684 in Canada. The conference ID number is 1743322. An audio replay will be available approximately two hours after the completion of the call at 1-877-344-7529 in the United States, 1-412-317-0088 for international, and 1-855-669-9658 in Canada. The Replay Conference ID number is 10153161. The recording will be available for replay through May 13, 2021. The webcast can be accessed at https://services.choruscall.com/links/clvt210429.html and will be available for replay.

Use of Non-GAAP Financial Measures
Non-GAAP results are not presentations made in accordance with U.S. generally accepted accounting principles (“GAAP”) and are presented only as a supplement to our financial statements based on GAAP. Non-GAAP financial information is provided to enhance the reader’s understanding of our financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP.  They are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.

We use non-GAAP measures in our operational and financial decision-making. We believe that such measures allow us to focus on what we deem to be a more reliable indicator of ongoing operating performance and our ability to generate cash flow from operations and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. These measures can be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of GAAP financial disclosures. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.

Definitions and reconciliations of non-GAAP measures, such as Adjusted Revenues, EBITDA, Adjusted EBITDA, Free Cash Flow, and Adjusted Free Cash Flow to the most directly comparable GAAP measures are provided within the schedules attached to this release.  Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all. 

Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Examples of forward-looking statements include, among others, statements we make regarding: guidance outlook and predictions relating to expected operating results, such as revenue growth and earnings; strategic actions such as acquisitions, joint ventures, and dispositions, including the anticipated benefits therefrom, and our success in integrating acquired businesses; anticipated levels of capital expenditures in future periods; our ability to successfully realize cost savings initiatives and transition services expenses; our belief that we have sufficiently liquidity to fund our ongoing business operations; expectations of the effect on our financial condition of claims, litigation, environmental costs, the COVID-19 pandemic and governmental responses thereto, contingent liabilities, and governmental and regulatory investigations and proceedings; and our strategy for customer retention, growth, product development, market position, financial results, and reserves. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.  

About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise.   For more information, please visit clarivate.com.

Reconciliation to Certain Non-GAAP Measures
(Amounts in tables may not sum due to rounding)


Adjusted Revenues

Adjusted Revenues excludes the impact of the deferred revenues purchase accounting adjustment (primarily recorded in connection with recent acquisitions).

The following table presents our calculation of Adjusted Revenues for the three and twelve months ended December 31, 2020 and 2019 and a reconciliation of this measure to our Revenues, net for the same periods:


Three Months Ended March 31,


Variance

(in millions, except percentages)


2021


2020


$


%

Revenues, net

$

428.4

$

240.6

$

187.8

78

%

Deferred revenues adjustment(1)

3.0

1.9

1.1

61

%

Adjusted revenues, net

$

431.5

$

242.5

$

189.0

78

%

(1)

Reflects the deferred revenues adjustment made as a result of purchase accounting.


Adjusted EBITDA

Adjusted EBITDA is calculated using Loss from operations before provision for income taxes, depreciation and amortization and interest income and expense adjusted to exclude acquisition or disposal-related transaction costs (such costs include net income from continuing operations before provision for income taxes, depreciation and amortization and interest income), share-based compensation, unrealized foreign currency gains/(losses), transition services agreement costs entered into with Thomson Reuters in 2016 (“Transition Services Agreement”), separation and integration costs, transformational and restructuring expenses, acquisition-related adjustments to deferred revenues, non-cash income/(loss) on equity and cost method investments, non-operating income or expense, the impact of certain non-cash and other items that are included in net income for the period that the Company does not consider indicative of its ongoing operating performance, and certain unusual items impacting results in a particular period.

The following table presents our calculation of Adjusted EBITDA for the three months ended March 31, 2021 and 2020 and reconciles these measures to our Loss from operations for the same periods:


Three Months Ended March 31,

(in millions)


2021


2020

Loss from operations

$

(34.2)

$

(28.3)

Depreciation and amortization

131.7

51.4

Transition services agreement costs(1)

1.6

Transition, transformation and integration expense(2)

2.2

Deferred revenues adjustment(3)

3.0

1.9

Transaction related costs(4)

(26.6)

26.7

Share-based compensation expense

10.7

17.5

Restructuring and impairment(5)

64.7

7.8

Other(6)

15.6

(2.5)

Adjusted EBITDA

$

164.8

$

78.2

Adjusted EBITDA Margin

38

%

32

%

(1)

In 2020, this is related to a new transition services agreement and offset by the reverse transition services agreement from the sale of MarkMonitor assets.

(2)

Includes costs incurred in connection with and after our separation from Thomson Reuters in 2016 relating to the implementation of our standalone company infrastructure and related cost-savings initiatives. These costs include mainly transition consulting, technology infrastructure, personnel and severance expenses relating to our standalone company infrastructure, which are recorded in Transition, integration, and other related expenses line-item of our income statement, as well as expenses related to the restructuring and transformation of our business following our separation from Thomson Reuters in 2016, mainly related to the integration of separate business units into one functional organization and enhancements in our technology.

(3)

Reflects the deferred revenues adjustment as a result of purchase accounting.

(4)

Includes costs incurred to complete business combination transactions, including acquisitions, dispositions and capital market activities and include advisory, legal, and other professional and consulting costs. During the three months ended March 31, 2021, the Company recognized mark to market adjustment gains of $27.7 million, primarily related to DRG contingent shares that were settled in March 2021.

(5)

Reflects costs incurred in connection with the initiative, following our merger with Churchill Capital Corp in 2019, to streamline our operations by simplifying our organization and focusing on two product groups. This also includes restructuring related costs following the acquisition of DRG and CPA Global in 2020.

(6)

Includes primarily the net impact of foreign exchange gains and losses related to the re-measurement of balances and other items that do not reflect our ongoing operating performance.


Free Cash Flow and Adjusted Free Cash Flow

Free cash flow is calculated using net cash provided by operating activities less capital expenditures. Adjusted free cash flow is calculated as free cash flow, less cash paid for transition services agreement, transition, transformation and integration expenses, transaction related costs and debt issuance costs offset by cash received for hedge accounting transactions. The following table reconciles our non-GAAP free cash flow and Adjusted free cash flow measure to net cash provided by operating activities:


Three Months Ended March 31,

(in millions)


2021


2020

Net cash provided by operating activities

$

174.0

$

46.1

Capital expenditures

(33.0)

(19.4)

Free Cash Flow

$

141.0

$

26.7

Cash paid for restructuring, transition, transformation and integration expense(1)

$

17.0

$

20.6

Cash paid for transaction related costs(2)

5.2

24.1

Cash paid for debt issuance costs

7.7

Cash received for hedge accounting transactions

(1.2)

Adjusted free cash flow

$

163.2

$

77.9

(1)

Includes cash payments in connection with and after our separation from Thomson Reuters in 2016 relating to the implementation of our standalone company infrastructure and related cost-savings initiatives. These cash payments include mainly transition consulting, technology infrastructure, personnel and severance expenses relating to our standalone company infrastructure, which are recorded in Transition, integration, and other related expenses line-item of our income statement, as well as cash payments related to the restructuring and transformation of our business following our separation from Thomson Reuters in 2016 mainly related to the integration of separate business units into one functional organization and enhancements in our technology. This also includes cash payments following our merger with Churchill Capital Corp in 2019, to streamline our operations by simplifying our organization and focusing on two product groups. This also includes restructuring related payments following the acquisition of DRG and CPA Global in 2020.

(2)

Includes costs incurred to complete business combination transactions, including acquisitions, dispositions and capital market activities and include advisory, legal, and other professional and consulting costs.


Organic Revenue

Growth in organic revenue, a non-GAAP measure, illustrates growth in businesses owned by the Company as of January 1, 2020, the beginning of the earliest period presented. We believe investors may find it useful to distinguish between revenue growth attributable to acquisitions and growth attributable to the ongoing business.

The following table presents the amounts of subscription. re-occurring and transactional revenues, as well as the drivers of variances between periods, including as a percentage of such revenues.


Variance Increase/(Decrease)


Percentage of Factors Increase/(Decrease)


Three Months Ended March 31,


Total Variance


(Dollars)


Total Variance


(Percentage)


Acquisitive


Disposal


FX Impact


Organic

(in millions, except percentages)


2021


2020

Subscription revenues

$

235.1

$

193.2

$

41.9

22

%

17

%

(4)

%

3

%

6

%

Re-occurring revenues

112.2

112.2

100

%

100

%

%

%

%

Transactional revenues

84.2

49.2

34.9

71

%

70

%

(12)

%

3

%

10

%

Deferred revenues adjustment(1)

(3.0)

(1.9)

(1.1)

(61)

%

NM

%

%

99

%

Revenues, net

$

428.4

$

240.6

$

187.8

78

%

73

%

(6)

%

3

%

8

%

Deferred revenues adjustment(1)

3.0

1.9

1.1

61

%

NM

%

%

(99)

%

Adjusted revenues, net

$

431.5

$

242.5

$

189.0

78

%

74

%

(6)

%

3

%

7

%


(1)

Reflects the deferred revenues adjustment made as a result of purchase accounting.

The following table presents our revenues by product segment for the periods indicated, as well as the drivers of variances between periods, including as a percentage of such revenues.


Variance Increase/(Decrease)


Percentage of Factors Increase/(Decrease)


Revenues by Product Segment


Three Months Ended March 31,


Total Variance (Dollars)


Total Variance (Percentage)


Acquisitive


Disposal


FX Impact


Organic

(in millions, except percentages)


2021


2020

Science product segment

$

191.3

$

147.3

$

44.0

30

%

16

%

0

%

4

%

10

%

IP product segment

240.1

95.2

144.9

152

%

163

%

(15)

%

2

%

2

%

Deferred revenues adjustment (1)

(3.0)

(1.9)

(1.1)

61

%

NM

0

%

0

%

99

%

Revenues, net

$

428.4

$

240.6

$

187.8

78

%

73

%

(6)

%

3

%

8

%

Deferred revenues adjustment (1)

3.0

1.9

1.1

61

%

NM

0

%

0

%

(99)

%

Adjusted revenues, net

$

431.5

$

242.5

$

189.0

78

%

74

%

(6)

%

3

%

7

%


(1)

Reflects the deferred revenues adjustment made as a result of purchase accounting.


2021 Outlook

The following table presents our calculation of Adjusted Revenues for the Outlook for 2021 and reconciles this measure to our Revenues, net for the same period:


Year Ending December 31, 2021 (Forecasted)

(in millions)


Low


High


Revenues, net

$

1,786.4

$

1,836.4

Deferred revenues adjustment(1)

3.6

3.6


Adjusted revenues, net

$

1,790.0

$

1,840.0


(1)

Reflects the deferred revenues adjustment made as a result of purchase accounting.

The following table presents our calculation of Adjusted EBITDA for the Outlook for 2021 and reconciles this measure to our Loss from operations for the same period:


Year Ending December 31, 2021 (Forecasted)

(in millions)


Low


High


Income from operations

$

178.2

$

213.2

Depreciation and amortization

545.8

545.8

Transition, transition services agreement, and integration expense(1)

40.3

40.3

Share-based compensation expense

26.0

26.0

Other

(0.3)

(0.3)


Adjusted EBITDA

$

790.0

$

825.0

Adjusted EBITDA Margin

44

%

45

%


(1)

Includes restructuring costs, other cost optimization activities, and payments and receipts under transition service agreements.

The following table presents our calculation of Free Cash Flow and Adjusted Free Cash Flow for the Outlook for 2021 and reconciles this measure to our Net cash provided by operating activities for the same period:


Year Ending December 31, 2021 (Forecasted)

(in millions)


Low


High


Net cash provided by operating activities

$

559.7

$

609.7

Capital expenditures

(151.7)

(151.7)

Free Cash Flow

408.0

458.0

Transition, transition services agreement, and integration expense(1)

42.0

42.0


Adjusted free cash flow

$

450.0

$

500.0


(1)

Includes cash payments related to restructuring and other cost optimization activities.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/clarivate-reports-first-quarter-2021-results-301279789.html

SOURCE Clarivate Plc

West Announces First-Quarter 2021 Results

– Conference Call Scheduled for 9 a.m. EDT Today –

PR Newswire

EXTON, Pa., April 29, 2021 /PRNewswire/ — West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance.

First-Quarter 2021 Summary (comparisons to prior-year period)

  • Net sales of $670.7 million grew 36.5%; organic sales growth was 31.1%.
  • Reported-diluted EPS of $1.99 increased 101%.
  • Adjusted-diluted EPS of $2.05 increased 103%.
  • The Company is raising full-year 2021 net sales guidance to a new range of $2.630 billion to $2.655 billion, compared to a prior range of $2.500 billion to $2.525 billion. The Company is raising full-year 2021 adjusted-diluted EPS guidance to a new range of $6.95 to $7.10, compared to a prior range of $6.00 to $6.15.

“Adjusted-diluted EPS” and “organic sales growth” are Non-U.S. GAAP measurements.  See discussion under the heading “Non-U.S. GAAP Financial Measures” in this release. 

“We delivered another solid performance in the first quarter with strong organic sales growth from both our base business as well as increased demand for our products associated with COVID-19 vaccines,” said Eric M. Green, President and Chief Executive Officer.  “I am proud of the relentless focus and consistent execution of our global team members to deliver critical components and solutions during these times. With a strong start to the year, we are raising our full-year financial guidance.  West will continue to play an integral role with our customers as they develop and bring new medicines to the market for a brighter future.”

Proprietary Products Segment
Net sales grew by 45.6% to $543.7 million.  Organic sales growth was 39.6% with currency translation increasing sales growth by 600 basis points.  High-value products (components and devices) represented more than 70% of segment sales and generated double-digit organic sales growth, led by customer demand for FluroTec®, Westar®, Daikyo® and NovaPure® components as well as for devices such as Daikyo Crystal Zenith® syringes and cartridges.

All three market units had double-digit organic sales growth, led by strong performance in the Biologics market unit.

Contract-Manufactured Products Segment
Net sales grew by 7.6% to $127.1 million.  Organic sales growth was 4.0% with currency translation increasing sales growth by 360 basis points.  Segment performance was led by sales of components for drug-injection delivery devices as well as diagnostic devices.

Financial Highlights
Operating cash flow was $88.7 million, an increase of 55.3%.  Capital expenditures in the quarter were $54.7 million.  Free cash flow (operating cash flow minus capital expenditures) was $34.0 million, an increase of 36%.

During the quarter, the Company repurchased 479,000 shares for $137.1 million at an average share price of $286.23 under its share repurchase program.

Our capital and financial resources, including overall liquidity, remain strong.  We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

Full-Year 2021 Financial Guidance

  • Full-year 2021 net sales are expected to be in a range of $2.630 billion to $2.655 billion, compared to a prior guidance range of $2.500 billion to $2.525 billion.
    • Organic sales growth is expected to be in a range of 19% to 20%, compared to a prior range of 13% to 14%.
    • Net sales guidance includes an estimated full-year 2021 benefit of $75 million based on current foreign exchange rates.
  • Full-year 2021 adjusted-diluted EPS is expected to be in a range of $6.95 to $7.10, compared to a prior range of $6.00 to $6.15.
    • Full-year adjusted-diluted EPS guidance range includes an estimated benefit of approximately $0.23 based on current foreign currency exchange rates.
    • The revised guidance includes a $0.15 EPS positive impact from first-quarter tax benefits from stock-based compensation.
    • For the remainder of the year, our EPS guidance range assumes a tax rate of 23% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-quarter 2021 would provide a positive adjustment to our full-year EPS guidance.

First-Quarter 2021 Conference Call
The Company will host a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time today.  To participate on the call please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 4285757.

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the “Investors” section.  Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select “Presentations” in the “Investors” section of the Company’s website.

An online archive of the broadcast will be available at the website three hours after the live call and will be available through Thursday, May 6, 2021, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International) and entering conference ID 4285757.

Forward-Looking Statements
Certain forward-looking statements appear in this release and include such words as “raising,” “believe,” “continue,” “remain,” “foreseeable,” “expected,” “to be,” “includes,” “estimated,” “assumes,” “potential,” “would provide,” and other similar terminology.  These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this release.  There is no certainty that actual results will be achieved in-line with current expectations.  These forward-looking statements involve a number of risks and uncertainties.  The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: the duration and severity of the global COVID-19 pandemic, including prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; customers’ changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories, including any re-prioritization of product needs due to COVID-19; other potential impacts from COVID-19, including interruptions or weaknesses in our supply chain, illness in our workforce and access to transport for our products; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; increased raw material costs; fluctuations in currency exchange; and the ability to meet development milestones with key customers.  This list of important factors is not all inclusive. For a description of certain additional factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, see Part I Item 1A , entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-U.S. GAAP Financial Measures
For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates.  Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.  We may also refer to financial results excluding the effects of unallocated items.  The re-measured results excluding effects from currency translation and excluding the effects of unallocated items are not in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and should not be used as a substitute for the comparable U.S. GAAP financial measures.  The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position.  A reconciliation of these adjusted Non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.


WEST PHARMACEUTICAL SERVICES, INC.


CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

(in millions, except per share data)


Three Months Ended



March 31,


2021

2020

Net sales


$670.7


100%

491.5

100%

Cost of goods and services sold


398.8


59

324.5

66

Gross profit


271.9


41

167.0

34

Research and development


12.2


2

10.7

2

Selling, general and administrative expenses


80.2


12

71.8

14

Other expense (income)


3.9


1

(3.5)

Operating profit


175.6


26

88.0

18

Interest expense, net


1.8



1.2

Other nonoperating (income) expense


(1.1)



0.3

Income before income taxes


174.9


26

86.5

18

Income tax expense


28.7


4

15.0

3

Equity in net income of affiliated companies


(5.0)


(1)­ ­

(2.8)

Net income


$151.2


23%

$74.3

15%

Net income per share:

Basic


$2.04

$1.01

Diluted


$1.99

$0.99

Average common shares outstanding


73.9

73.9

Average shares assuming dilution


75.8

75.5

 


WEST PHARMACEUTICAL SERVICES


REPORTING SEGMENT INFORMATION

(UNAUDITED)


(in millions)


Three Months Ended


March 31,


Net Sales:


2021

2020

Proprietary Products


$543.7

$373.5

Contract-Manufactured Products


127.1

118.1

Eliminations


(0.1)

(0.1)

Consolidated Total


$670.7

$491.5


Gross Profit:

Proprietary Products


$251.9

$150.1

Contract-Manufactured Products


20.0

16.9


Gross Profit


$271.9

$167.0


   
Gross Profit Margin



40.5%


34.0%


Operating Profit (Loss):

Proprietary Products


$182.6

$93.2

Contract-Manufactured Products


16.4

12.8

Stock-based compensation expense


(5.9)

(5.4)

General corporate costs


(13.9)

(12.6)


Adjusted Operating Profit


$179.2

$88.0



  

Adjusted Operating Profit Margin



26.7%


17.9%

Other unallocated items


(3.6)


Reported Operating Profit


$175.6

$88.0



  

Reported Operating Profit Margin



26.2%


17.9%

 


WEST PHARMACEUTICAL SERVICES


RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)


Please refer to “Non-U.S. GAAP Financial Measures” for more information


(in millions, except per share data)


Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS


Three months ended March 31, 2021

Operating
profit

Income
tax
expense

Net
income

Diluted
EPS

Reported (U.S. GAAP)

$175.6

$28.7

$151.2

$1.99

Unallocated items:

Restructuring and related charges (1)

1.2

0.2

1.0

0.01

Pension Settlement (2)

0.2

0.5

0.01

Amortization of Acquisition-related Intangible Assets (3)

0.2

0.7

0.01

Cost investment impairment

2.2

2.2

0.03

Adjusted (Non-U.S. GAAP)

$179.2

$29.1

$155.6

$2.05


Three months ended March 31, 2020

Operating
profit

Income
tax
expense

Net
income

Diluted
EPS

Reported (U.S. GAAP)

$88.0

$15.0

$74.3

$0.99

Pension Settlement (2)

0.3

1.1

0.01

Amortization of Acquisition-related Intangible Assets (3)

1.0

0.01

Adjusted (Non-U.S. GAAP)

$88.0

$15.3

$76.4

$1.01


(1)

During the three months ended March 31, 2021, the Company recorded $1.2 million in restructuring and related charges in connection with its 2020 plan to optimize certain organizational structures within the Company.


(2)

During the three months ended March 31, 2021 and March 31, 2020, the Company recorded a pension settlement charge of $0.6 million and $1.4 million, respectively, within other nonoperating (income) expense, as it determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting.


(3)

During the three months ended March 31, 2021, the Company recorded $0.2 million of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020. During the three months ended March 31, 2021 and 2020 the Company recorded $0.5 million and $1.0 million of amortization expense, respectively, in association with an acquisition of increased ownership interest in Daikyo.

 


WEST PHARMACEUTICAL SERVICES


RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)


Please refer to “Non-U.S. GAAP Financial Measures” for more information


(in millions, except per share data)


Reconciliation of Net Sales to Organic Net Sales (4)


Three months ended March 31, 2021

Proprietary

CM

Eliminations

Total

Reported net sales (U.S. GAAP)

$543.7

$127.1

$(0.1)

$670.7

Effect of changes in currency translation rates

22.2

4.3

26.5

Organic net sales (Non-U.S. GAAP) (4)

$565.9

$131.4

$(0.1)

$697.2


(4)

Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.

 


WEST PHARMACEUTICAL SERVICES


RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)


Please refer to “Non-U.S. GAAP Financial Measures” for more information


(in millions, except per share data)


Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance

2020 Actual

2021 Guidance

% Change

Reported-diluted EPS (U.S. GAAP)

$4.57

$6.86 to $7.01

50.1% to 53.4%

Restructuring and related charges

0.07

0.01

Pension settlement

0.04

0.01

Amortization of acquisition-related intangible assets

0.05

0.04

Cost investment impairment

0.03

0.03

Adjusted-diluted EPS (Non-U.S. GAAP) (5)

$4.76

$6.95 to $7.10

46.0% to 49.2%


Notes:

See “Full-year 2021 Financial Guidance” and “Non-U.S. GAAP Financial Measures” in today’s press release for additional information regarding adjusted-diluted EPS.

(5)

We have opted not to forecast 2021 tax benefits from stock-based compensation in upcoming quarters, as they are out of the Company’s control.  Instead, we recognize the benefits as they occur.  In the first-quarter 2021, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.15.  Any future tax benefits associated with stock-based compensation that we receive in 2021 would provide a positive adjustment to our full-year EPS guidance.  In 2020, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.27. 

 


WEST PHARMACEUTICAL SERVICES


CASH FLOW ITEMS

(UNAUDITED)


(in millions)

Three Months Ended March 31,

2021

2020

Depreciation and amortization

$29.1

$26.0

Operating cash flow

$88.7

$57.1

Capital expenditures

$54.7

$32.1

 


WEST PHARMACEUTICAL SERVICES


FINANCIAL CONDITION

(UNAUDITED)


(in millions)

As of

March 31, 2021

As of

December 31, 2020

Cash and cash equivalents

$483.7

$615.5

Accounts receivable, net

$465.7

$385.3

Inventories

$310.2

$321.3

Accounts payable

$204.3

$213.1

Debt

$254.6

$255.2

Equity

$1,829.0

$1,854.5

Working capital

$844.2

$870.3

Trademark Notices

Trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., in the United States and other jurisdictions, unless noted otherwise.

Daikyo
®
,
 Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd.  Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/west-announces-first-quarter-2021-results-301279684.html

SOURCE West Pharmaceutical Services, Inc.

San Jose Sharks Successfully Install Opteon™ Refrigerant in New Ice Refrigeration Systems at SAP Center at San Jose

NHL Arena Advances Sustainability with Opteon™ XP10 (R-513A) in Trane Chillers for both Ice Making and HVAC Systems

PR Newswire

WILMINGTON, Del., April 29, 2021 /PRNewswire/ — The Chemours Company (NYSE: CC), a global chemistry company with leading positions in Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials and Chemical Solutions, today announced the successful installation and use of Opteon™ refrigerant at SAP Center at San Jose, home of the San Jose Sharks® in California.  The facility leveraged the use of Opteon™ XP10 in both ice making and building HVAC systems from Trane® Technologies, one of the world’s leading HVAC equipment manufacturers. This installation marks the second National Hockey League (NHL®) Club in two years that has upgraded to Opteon™ for its performance, reliability, safety, environmental properties, and cost effectiveness. 

“SAP Center at San Jose is a world-class sports and entertainment venue, hosting San Jose Sharks (NHL) and San Jose Barracuda (AHL) games, figure skating competitions and exhibitions, and family shows on ice throughout the year. When we needed to upgrade the refrigeration systems at the venue, we had a variety of options – but landed on Opteon™,” said Jon Gustafson, Senior Vice President & General Manager, SAP Center at San Jose. “Through installation, startup and initial ice making – and return to play, the performance of Opteon™ has met or exceeded our expectations.  With the environment top of mind, we went with Opteon™ because it’s a proven solution that had the best balance our organization was looking for.”

Opteon™, the preferred refrigerant of the NHL®, is a non-ozone depleting and low global warming potential (GWP) solution that offers an environmentally and economically sustainable solution to make high-quality ice in professional and community rinks across North America. With various refrigerant options to consider when replacing their aging system, the forward-thinking San Jose Sharks® chose to be a leader in their community, years ahead of 2024, when facilities in California replacing ice plant  and HVAC chillers will need to choose a refrigerant with < 750 GWP.  

“We are proud to work with the San Jose Sharks and Trane® Technologies to provide a safer, more sustainable arena for players, fans and the surrounding community,” said Alisha Bellezza, President, Thermal & Specialized Solutions at ChemoursTM. “Chemours is committed to supporting NHL and community rinks alike with our Opteon™ refrigerants. The SAP Center upgrade represents another arena added to the rinks across North America that have already converted to Opteon™.” 

The National Hockey League (NHL®) and Chemours partnership continues to inspire environmental progress in the sports community through educating owners and operators about the importance of transitioning to low-GWP, non-ozone depleting refrigerant solutions for their refrigeration and HVAC systems. The partnership is helping to transform the game of ice hockey through innovation and leadership, thereby ensuring that all levels of hockey continue to thrive. 

For more information, please visit https://pages.chemours.com/optforbetter-nhl

About The Chemours Company

The Chemours Company (Chemours or the Company) (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration, and air conditioning, transportation, semiconductor, and consumer electronics, general industrial, mining and oil and gas. Our flagship products include prominent brands such as Ti-Pure™, Opteon™, Freon™, Nafion™, Krytox™, Teflon™, and Viton™. In 2019, Chemours was named to Newsweek’s list of America’s Most Responsible Companies. The company has approximately 6,500 employees and 30 manufacturing sites serving approximately 3,300 customers in approximately 120 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

For more information, we invite you to visit chemours.com or follow us on Twitter @Chemours or LinkedIn

Forward Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control. In addition, the current COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets, which has had and we expect will continue to have a negative impact on our financial results. The full extent and impact of the pandemic is unknown and to date has included extreme volatility in financial and commodity markets, a significant slowdown in economic activity, and increased predictions of a global recession. The public and private sector response has led to significant restrictions on travel, temporary business closures, quarantines, stock market volatility, and a general reduction in consumer and commercial activity globally. Matters outside our control have affected our business and operations and may or may continue to limit travel of employees to our business units domestically and internationally, adversely affect the health and welfare of our personnel, significantly reduce the demand for our products, hinder our ability to provide goods and services to customers, cause disruptions in our supply chains, adversely affect our business partners or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2020. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

CONTACT:

NEWS MEDIA 
Thomas Sueta
Director, Corporate Communications
+1.302.773.3903
[email protected]  

INVESTORS 
Jonathan Lock 
VP, Corporate Development and Investor Relations
+1.302.773.2263
 
[email protected] 

NHL and the NHL Shield are registered trademarks of the National Hockey League.  San Jose Sharks name and primary logo are registered trademarks of the NHL team. All Rights Reserved.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/san-jose-sharks-successfully-install-opteon-refrigerant-in-new-ice-refrigeration-systems-at-sap-center-at-san-jose-301279891.html

SOURCE The Chemours Company

Patterson-UTI Energy Reports Financial Results for the Three Months Ended March 31, 2021

PR Newswire

HOUSTON, April 29, 2021 /PRNewswire/ —  PATTERSON-UTI ENERGY, INC. (NASDAQ: PTEN) today reported financial results for the three months ended March 31, 2021.  The Company reported a net loss of $106 million, or $0.57 per share, for the first quarter of 2021, compared to a net loss of $435 million, or $2.28 per share, for the first quarter of 2020.  Revenues for the first quarter of 2021 were $241 million, compared to $446 million for the first quarter of 2020.

Andy Hendricks, Patterson-UTI’s Chief Executive Officer, stated, “First quarter financial results exceeded our expectations, as revenues and adjusted EBITDA improved sequentially, despite challenges from the extreme winter storm in the southwest.  Our contract drilling and directional drilling businesses posted better than expected results in the first quarter.  Excluding the impact of the winter storm, our pressure pumping results would have been consistent with our expectations.”

Mr. Hendricks continued, “In contract drilling, our average rig count for the first quarter improved to 69 rigs from 62 rigs in the fourth quarter.  Our rig count ended the first quarter at 71 rigs, and we have already activated two rigs in the second quarter.  Considering the timing of additional rig reactivations, as well as idle but contracted rigs rolling off contract, we expect to average 73 rigs for the second quarter.  We expect our rig count will reach approximately 80 rigs over the next three months, with a substantial portion of the rig count increase in June and July.   

“Average rig margin per day for the first quarter of $8,750, included a benefit of $6.0 million, or $960 per day, related to a sales and use tax refund, and a benefit of $2.3 million, or $370 per day, for revenue that was not recognized in 2020 due to concerns about collectability.  However, even after excluding both of these benefits, average rig margin per day exceeded our expectation due to a combination of both higher than expected revenues and lower than expected costs.  Both average rig revenue per day and operating cost per day increased sequentially, as the proportion of rigs that were idle but contracted decreased to 7% in the first quarter from 16% in the fourth quarter.          

“As of March 31, 2021, we had term contracts for drilling rigs providing for approximately $240 million of future dayrate drilling revenue.  Based on contracts currently in place, we expect an average of 39 rigs operating under term contracts during the second quarter, and an average of 27 rigs operating under term contracts during the four quarters ending March 31, 2022.   

“In pressure pumping, first quarter results were significantly impacted by the winter storm.  Revenues decreased to $75.8 million during the first quarter and gross margin decreased to a loss of $0.7 million.  We averaged seven active spreads during the first quarter, with an effective utilization of 5.5 spreads.  Downtime was primarily associated with the winter storm and the mobilization of a spread from the northeast to Texas.  In the second quarter, we expect utilization to improve and we plan to reactivate an additional spread late in the quarter for dedicated work.        

“In directional drilling, revenues during the first quarter increased sequentially to $19.7 million from $16.9 million in the fourth quarter.  Gross margin improved in the first quarter to $3.0 million, or 15% of revenues, from $2.2 million, or 13% of revenues, in the fourth quarter, as the business continues to improve.”     

Mr. Hendricks concluded, “Drilling and completion activity continues to improve at a moderate pace.  While operators continue to exercise capital discipline, we see increasing activity across all classes of operators during the year.  We believe that Patterson-UTI is well positioned given our performance and technology offerings, including solutions to help E&P companies improve efficiencies and reduce wellsite emissions through the use of alternative fuel sources.” 

The Company declared a quarterly dividend on its common stock of $0.02 per share, payable on June 17, 2021, to holders of record as of June 3, 2021.

Financial results for the three months ended March 31, 2020 include pre-tax, non-cash charges totaling $406 million ($349 million after-tax, or $1.83 per share).  These charges include a $395 million impairment charge for goodwill and a $10.6 million impairment charge related to certain of the Company’s E&P assets.

All references to “per share” in this press release are diluted earnings per common share as defined within Accounting Standards Codification Topic 260.

The Company’s quarterly conference call to discuss the operating results for the quarter ended March 31, 2021, is scheduled for today, April 29, 2021, at 9:00 a.m. Central Time. The dial-in information for participants is (844) 494-0002 (Domestic) and (647) 253-8640 (International).  The conference ID for both numbers is 7069802.  The call is also being webcast and can be accessed through the Investor Relations section of the Company’s website at investor.patenergy.com.  A replay of the conference call will be on the Company’s website for two weeks. 

About Patterson-UTI

Patterson-UTI is a leading provider of oilfield services and products to oil and natural gas exploration and production companies in the United States, including contract drilling, pressure pumping and directional drilling services.  For more information, visit www.patenergy.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements which are protected as forward-looking statements under the Private Securities Litigation Reform Act of 1995 that are not limited to historical facts, but reflect Patterson-UTI’s current beliefs, expectations or intentions regarding future events.  Words such as “anticipate,” “believe,” “budgeted,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “potential,” “project,” “pursue,” “should,” “strategy,” “target,” or “will,” and similar expressions are intended to identify such forward-looking statements.  The statements in this press release that are not historical statements, including statements regarding Patterson-UTI’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws.  These statements are subject to numerous risks and uncertainties, many of which are beyond Patterson-UTI’s control, which could cause actual results to differ materially from the results expressed or implied by the statements.  These risks and uncertainties include, but are not limited to: adverse oil and natural gas industry conditions; including the rapid decline in crude oil prices as a result of economic repercussions from the COVID-19 pandemic; global economic conditions; volatility in customer spending and in oil and natural gas prices that could adversely affect demand for Patterson-UTI’s services and their associated effect on rates; excess availability of land drilling rigs, pressure pumping and directional drilling equipment, including as a result of reactivation, improvement or construction; competition and demand for Patterson-UTI’s services; strength and financial resources of competitors; utilization, margins and planned capital expenditures; liabilities from operational risks for which Patterson-UTI does not have and receive full indemnification or insurance; operating hazards attendant to the oil and natural gas business; failure by customers to pay or satisfy their contractual obligations (particularly with respect to fixed-term contracts); the ability to realize backlog; specialization of methods, equipment and services and new technologies, including the ability to develop and obtain satisfactory returns from new technology; the ability to retain management and field personnel; loss of key customers; shortages, delays in delivery, and interruptions in supply, of equipment and materials; cybersecurity events; synergies, costs and financial and operating impacts of acquisitions; difficulty in building and deploying new equipment; governmental regulation; climate legislation, regulation and other related risks; environmental, social and governance practices, including the perception thereof; environmental risks and ability to satisfy future environmental costs; technology-related disputes; legal proceedings and actions by governmental or other regulatory agencies; the ability to effectively identify and enter new markets; weather; operating costs; expansion and development trends of the oil and natural gas industry; ability to obtain insurance coverage on commercially reasonable terms; financial flexibility; interest rate volatility; adverse credit and equity market conditions; availability of capital and the ability to repay indebtedness when due; stock price volatility; and compliance with covenants under Patterson-UTI’s debt agreements.

Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in Patterson-UTI’s SEC filings.  Patterson-UTI’s filings may be obtained by contacting Patterson-UTI or the SEC or through Patterson-UTI’s website at http://www.patenergy.com or through the SEC’s Electronic Data Gathering and Analysis Retrieval System (EDGAR) at http://www.sec.gov.  Patterson-UTI undertakes no obligation to publicly update or revise any forward-looking statement.


PATTERSON-UTI ENERGY, INC.

Condensed Consolidated Statements of Operations

(unaudited, in thousands, except per share data)


Three Months Ended


March 31,


2021


2020


REVENUES

$

240,929

$

445,927


COSTS AND EXPENSES:

Direct operating costs

182,751

326,628

Depreciation, depletion, amortization and impairment

152,882

186,797

Impairment of goodwill

395,060

Selling, general and administrative

22,558

30,346

Credit loss expense

1,055

Other operating expenses, net

265

451

Total costs and expenses

358,456

940,337

OPERATING LOSS

(117,527)

(494,410)


OTHER INCOME (EXPENSE):

Interest income

139

657

Interest expense, net of amount capitalized

(10,009)

(11,224)

Other

14

85

Total other expense

(9,856)

(10,482)

LOSS BEFORE INCOME TAXES

(127,383)

(504,892)

INCOME TAX BENEFIT

(20,970)

(70,170)

NET LOSS

$

(106,413)

$

(434,722)


NET LOSS PER COMMON SHARE:

Basic

$

(0.57)

$

(2.28)

Diluted

$

(0.57)

$

(2.28)


WEIGHTED AVERAGE NUMBER OF COMMON


   SHARES OUTSTANDING:

Basic

187,677

190,674

Diluted

187,677

190,674

CASH DIVIDENDS PER COMMON SHARE

$

0.02

$

0.04

 


PATTERSON-UTI ENERGY, INC.

Additional Financial and Operating Data

(unaudited, dollars in thousands)


Three Months Ended


Three Months
Ended


March 31,


December 31,


2021


2020


2020


Contract Drilling:

Revenues

$

133,501

$

267,364

$

115,574

Direct operating costs

$

79,378

$

163,420

$

71,158

Margin (1)

$

54,123

$

103,944

$

44,416

Other operating expenses (income), net

$

12

$

$

(30)

Selling, general and administrative

$

1,058

$

1,464

$

982

Depreciation, amortization and impairment

$

101,674

$

111,438

$

104,928

Impairment of goodwill

$

$

395,060

$

Operating loss

$

(48,621)

$

(404,018)

$

(61,464)

Operating days

6,183

11,235

5,720

Average revenue per operating day

$

21.59

$

23.80

$

20.21

Average direct operating costs per operating day

$

12.84

$

14.55

$

12.44

Average margin per operating day (1)

$

8.75

$

9.25

$

7.77

Average rigs operating

69

123

62

Capital expenditures

$

11,427

$

49,445

$

3,589


Pressure Pumping:

Revenues

$

75,839

$

125,107

$

79,498

Direct operating costs

$

76,510

$

114,855

$

75,417

Margin (2)

$

(671)

$

10,252

$

4,081

Selling, general and administrative

$

1,683

$

3,067

$

1,807

Depreciation, amortization and impairment

$

37,385

$

42,671

$

34,044

Operating loss

$

(39,739)

$

(35,486)

$

(31,770)

Average active spreads (3)

7

10

7

Effective utilization (4)

5.5

7.7

6.3

Fracturing jobs

71

89

72

Other jobs

200

209

195

Total jobs

271

298

267

Average revenue per fracturing job

$

977.89

$

1,359.39

$

1,019.85

Average revenue per other job

$

32.05

$

19.72

$

31.12

Average revenue per total job

$

279.85

$

419.82

$

297.75

Average costs per total job

$

282.32

$

385.42

$

282.46

Average margin per total job (2)

$

(2.48)

$

34.40

$

15.28

Margin as a percentage of revenues (2)

(0.9)

%

8.2

%

5.1

%

Capital expenditures

$

4,068

$

14,280

$

3,798

 


PATTERSON-UTI ENERGY, INC.

Additional Financial and Operating Data

(unaudited, dollars in thousands)


Three Months Ended


Three Months Ended


March 31,


December 31,


2021


2020


2020


Directional Drilling:

Revenues

$

19,670

$

34,485

$

16,858

Direct operating costs

$

16,637

$

32,329

$

14,702

Margin (5)

$

3,033

$

2,156

$

2,156

Selling, general and administrative

$

1,459

$

2,330

$

1,070

Depreciation, amortization and impairment

$

6,497

$

10,421

$

6,806

Operating loss

$

(4,923)

$

(10,595)

$

(5,720)

Margin as a percentage of revenues (5)

15.4

%

6.3

%

12.8

%

Capital expenditures

$

104

$

2,008

$

119


Other Operations:

Revenues

$

11,919

$

18,971

$

8,871

Direct operating costs

$

10,226

$

16,024

$

8,015

Margin (6)

$

1,693

$

2,947

$

856

Selling, general and administrative

$

425

$

1,459

$

570

Depreciation, depletion, amortization and impairment

$

5,824

$

20,259

$

6,424

Operating loss

$

(4,556)

$

(18,771)

$

(6,138)

Capital expenditures

$

2,744

$

5,264

$

2,602


Corporate:

Selling, general and administrative

$

17,933

$

22,026

$

16,490

Depreciation

$

1,502

$

2,008

$

1,507

Credit loss expense

$

$

1,055

$

Other operating expenses, net

$

253

$

451

$

1,109

Capital expenditures

$

180

$

931

$

330


Total capital expenditures

$

18,523

$

71,928

$

10,438


(1)

For Contract Drilling, margin is defined as revenues less direct operating costs and excludes depreciation, amortization and impairment, impairment of goodwill, other operating expenses (income), net and selling, general and administrative expenses. Average margin per operating day is defined as margin divided by operating days.


(2)

For Pressure Pumping, margin is defined as revenues less direct operating costs and excludes depreciation, amortization and impairment and selling, general and administrative expenses. Average margin per total job is defined as margin divided by total jobs. Margin as a percentage of revenues is defined as margin divided by revenues.


(3)

Average active spreads is the average number of spreads that were crewed and actively marketed during the period.


(4)

Effective utilization is calculated as total pumping days during the quarter divided by 75 days, which we consider full effective utilization for a spread.


(5)

For Directional Drilling, margin is defined as revenues less direct operating costs and excludes depreciation, amortization and impairment and selling, general and administrative expenses. Margin as a percentage of revenues is defined as margin divided by revenues.


(6)

For Other Operations, margin is defined as revenues less direct operating costs and excludes depreciation, depletion, amortization and impairment, and selling, general and administrative expenses.

 


March 31,


December 31,


Selected Balance Sheet Data (unaudited, in thousands):


2021


2020

Cash and cash equivalents

$

214,144

$

224,915

Current assets

$

487,602

$

477,956

Current liabilities

$

272,260

$

273,722

Working capital

$

215,342

$

204,234

Long-term debt

$

901,689

$

901,484

 


PA
TTERSON-UTI ENERGY, INC.

Non-U.S. GAAP Financial Measures

(unaudited, dollars in thousands)


Three Months Ended


Three Months Ended


March 31,


December 31,


2021


2020


2020


Adjusted Earnings Before Interest, Taxes, Depreciation


   and Amortization (Adjusted EBITDA)(1):

Net loss

$

(106,413)

$

(434,722)

$

(106,527)

Income tax benefit

(20,970)

(70,170)

(24,846)

Net interest expense

9,870

10,567

7,249

Depreciation, depletion, amortization and impairment

152,882

186,797

153,709

Impairment of goodwill

395,060

Adjusted EBITDA

$

35,369

$

87,532

$

29,585

Total revenues

$

240,929

$

445,927

$

220,801

Adjusted EBITDA margin

14.7

%

19.6

%

13.4

%


Adjusted EBITDA by operating segment:

Contract drilling

$

53,053

$

102,480

$

43,464

Pressure pumping

(2,354)

7,185

2,274

Directional drilling

1,574

(174)

1,086

Other operations

1,268

1,488

286

Corporate

(18,172)

(23,447)

(17,525)

Consolidated Adjusted EBITDA

$

35,369

$

87,532

$

29,585


(1)

Adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) is not defined by accounting principles generally accepted in the United States of America (“U.S. GAAP”). We define Adjusted EBITDA as net loss plus net interest expense, income tax benefit and depreciation, depletion, amortization and impairment expense (including impairment of goodwill). We present Adjusted EBITDA because we believe it provides to both management and investors additional information with respect to the performance of our fundamental business activities and a comparison of the results of our operations from period to period and against our peers without regard to our financing methods or capital structure. We exclude the items listed above from net loss in arriving at Adjusted EBITDA because these amounts can vary substantially from company to company within our industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired. Adjusted EBITDA should not be construed as an alternative to the U.S. GAAP measure of net income (loss). Our computations of Adjusted EBITDA may not be the same as similarly titled measures of other companies.

 


PATTERSON-UTI ENERGY, INC.

Non-Cash Charges

Three Months Ended March 31, 2020

(unaudited, in thousands, except per share data)


Total


Per Share

Impairment of goodwill

$

395,060

Impairment of E&P assets

10,551

Pre-tax amount

405,611

Income tax benefit

(56,380)

After tax amount

$

349,231

$

1.83

Weighted average number of common shares

outstanding, excluding non-vested shares

of restricted stock

190,674

Add dilutive effect of potential common shares

Weighted average number of diluted common

shares outstanding

190,674

Effective income tax rate

13.9

%

 

Cision View original content:http://www.prnewswire.com/news-releases/patterson-uti-energy-reports-financial-results-for-the-three-months-ended-march-31-2021-301279770.html

SOURCE PATTERSON-UTI ENERGY, INC.

M.D.C. Holdings Announces First Quarter 2021 Results

201% increase in net income driven by home sale revenues growth of 49% and a 200 basis point expansion to our gross margin from home sales to 21.9%

PR Newswire

DENVER, April 29, 2021 /PRNewswire/ — M.D.C Holdings, Inc. (NYSE: MDC), one of the nation’s leading homebuilders, announced results for the quarter ended March 31, 2021.

Larry A. Mizel, MDC’s Executive Chairman, stated, “MDC delivered another quarter of strong profitability, generating net income of $111 million, or $1.51 per diluted share. Home sale revenues grew 49% year-over-year on a 41% increase in closings and 6% rise in average selling prices. We continue to see heightened demand for our homes, as evidenced by the 34% year-over-year increase to unit orders for the quarter. The only constraint to our sales efforts are ones that we are imposing on ourselves, in an effort to balance orders and pricing to best manage our backlog. These efforts resulted in a 200 basis point expansion to our gross margin from home sales in the quarter to 21.9%. We have also been successful in leveraging our overhead expenses, lowering our SG&A ratio by 180 basis points in the quarter to 11.0%. Given the size of our quarter-ending backlog and the current state of the housing market, we believe MDC is in a great position to deliver excellent results for the full year.”

Mr. Mizel continued, “We continue to run our business in a prudent manner by focusing on steady growth in each of our markets while maintaining a strong capital position. This focus was recognized by S&P Global Ratings earlier this month, which upgraded our credit rating to investment grade. We believe this is validation for our long-term approach to the business and the strength of our balance sheet, which we feel benefits both debt and equity investors over time.”

David D. Mandarich, MDC’s President and Chief Executive Officer stated, “While the entire industry is benefiting from the ongoing imbalance between housing supply and demand, we believe MDC is uniquely positioned to succeed in today’s market thanks to our continued focus on more affordable price points and our build-to-order model. There is a real need for additional housing in this country, especially for people looking to buy their first home, and a majority of our communities cater to these buyers. There is also a desire for new home customization among these buyers, which is another benefit that our business model offers. We believe these two trends will be in place for the foreseeable future, giving us a great runway for continued success.”

2021 First Quarter Highlights and Comparisons to 2020 First Quarter

Home sale revenues increased 49% to $1.04 billion from $697.1 million

º

Unit deliveries up 41% to 2,178

º

Average selling price of deliveries up 6% to $478,000

Homebuilding pretax income increased 129% to $113.5 million from $49.7 million

º

Gross margin from home sales increased 200 basis points to 21.9% from 19.9%

º

Selling, general and administrative expenses as a percentage of home sale revenues (“SG&A rate”) improved by 180 basis points to 11.0%

Financial services pretax income increased $31.9 million to $30.8 million, compared to a pretax loss of $1.1 million in the first quarter of 2020

Net income of $110.7 million, or $1.51 per diluted share, up 201% from $36.8 million or $0.52 per diluted share*

º

Effective tax rate of 23.3% vs. 24.3%

Dollar value of net new orders increased 50% to $1.64 billion from $1.09 billion

º

Unit net orders increased 34% to 3,209

º

Average selling price of net orders up 12%

Dollar value of ending backlog up 81% to $3.93 billion from $2.17 billion

º

Unit backlog increased 65% to 7,686

º

Average selling price of homes in backlog up 9%

* Per share amount for the 2020 first quarter has been adjusted for the 8% stock dividend declared and paid in the 2021 first quarter.

2021 Outlook and Other Selected Information
1

Home deliveries for the 2021 second quarter between 2,500 and 2,700

º

Average selling price for 2021 second quarter unit deliveries of approximately $500,000

º

Gross margin from home sales for the 2021 second quarter of approximately 22.5% (excluding impairments and warranty adjustments)

Full year 2021 home deliveries between 10,000 and 11,000

Active subdivision count goal of at least 10% growth during 2021 (from December 31, 2020 to December 31, 2021)

Lots controlled of 32,023 at March 31, 2021, up 18% year-over-year

Quarterly cash dividend of forty cents ($0.40) per share declared on April 26, 2021, up 31% year-over-year (after adjusting for 8% stock dividend in March 2021)


1 See “Forward-Looking Statements” below.


About MDC

M.D.C. Holdings, Inc. was founded in 1972. MDC’s homebuilding subsidiaries, which operate under the name Richmond American Homes, have built and financed the American Dream for more than 210,000 homebuyers since 1977.  MDC’s commitment to customer satisfaction, quality and value is reflected in each home its subsidiaries build. MDC is one of the largest homebuilders in the United States. Its subsidiaries have homebuilding operations across the country, including the metropolitan areas of Denver, Colorado Springs, Salt Lake City, Las Vegas, Phoenix, Tucson, RiversideSan Bernardino, Los Angeles, San Diego, Orange County, San Francisco Bay Area, Sacramento, Washington D.C., Baltimore, Orlando, Jacksonville, Seattle, Portland and Boise. The Company’s subsidiaries also provide mortgage financing, insurance and title services, primarily for Richmond American homebuyers, through HomeAmerican Mortgage Corporation, American Home Insurance Agency, Inc. and American Home Title and Escrow Company, respectively. M.D.C. Holdings, Inc. is traded on the New York Stock Exchange under the symbol “MDC.” For more information, visit www.mdcholdings.com.


Forward-Looking Statements

Certain statements in this release, including any statements regarding our business, financial condition, results of operation, cash flows, strategies and prospects, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of MDC to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among other things, (1) general economic conditions, including the impact of the COVID-19 pandemic, changes in consumer confidence, inflation or deflation and employment levels; (2) changes in business conditions experienced by MDC, including restrictions on business activities resulting from the COVID-19 pandemic, cancellation rates, net home orders, home gross margins, land and home values and subdivision counts; (3) changes in interest rates, mortgage lending programs and the availability of credit; (4) changes in the market value of MDC’s investments in marketable securities; (5) uncertainty in the mortgage lending industry, including repurchase requirements associated with HomeAmerican Mortgage Corporation’s sale of mortgage loans (6) the relative stability of debt and equity markets; (7) competition; (8) the availability and cost of land and other raw materials used by MDC in its homebuilding operations; (9) the availability and cost of performance bonds and insurance covering risks associated with our business; (10) shortages and the cost of labor; (11) weather related slowdowns and natural disasters; (12) slow growth initiatives; (13) building moratoria; (14) governmental regulation, including orders addressing the COVID-19 pandemic, the interpretation of tax, labor and environmental laws; (15) terrorist acts and other acts of war; (16) changes in energy prices; and (17) other factors over which MDC has little or no control. Additional information about the risks and uncertainties applicable to MDC’s business is contained in MDC’s Form 10-Q for the quarter ended March 31, 2021, which is scheduled to be filed with the Securities and Exchange Commission today.  All forward-looking statements made in this press release are made as of the date hereof, and the risk that actual results will differ materially from expectations expressed in this press release will increase with the passage of time. MDC undertakes no duty to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in our subsequent filings, releases or webcasts should be consulted.


M.D.C. HOLDINGS, INC.


Consolidated Statements of Operations and Comprehensive Income

(Unaudited)

Three Months Ended

March 31,

2021

2020

(Dollars in thousands, except per share amounts)


Homebuilding:

Home sale revenues

$

1,041,858

$

697,085

Home cost of sales

(813,888)

(558,647)

Gross profit

227,970

138,438

Selling, general and administrative expenses

(114,993)

(89,321)

Interest and other income

967

1,889

Other expense

(437)

(1,337)

Homebuilding pretax income

113,507

49,669


Financial Services:

Revenues

45,023

21,886

Expenses

(15,105)

(10,929)

Other income (expense), net

887

(12,064)


Financial services pretax income (loss)

30,805

(1,107)

Income before income taxes

144,312

48,562

Provision for income taxes

(33,622)

(11,802)

Net income

$

110,690

$

36,760

Comprehensive income

$

110,690

$

36,760

Earnings per share:

Basic

$

1.58

$

0.54

Diluted

$

1.51

$

0.52

Weighted average common shares outstanding:

Basic

69,790,927

67,490,537

Diluted

72,788,177

70,125,723

Dividends declared per share

$

0.37

$

0.31

 


M.D.C. HOLDINGS, INC.


Consolidated Balance Sheets

(Unaudited) 

March 31,

2021

December 31,

2020

(Dollars in thousands, except

per share amounts)


ASSETS


Homebuilding:

Cash and cash equivalents

$

678,194

$

411,362

Restricted cash

17,314

15,343

Trade and other receivables

107,823

72,466

Inventories:

Housing completed or under construction

1,705,424

1,486,587

Land and land under development

1,310,721

1,345,643

Total inventories

3,016,145

2,832,230

Property and equipment, net

60,394

61,880

Deferred tax asset, net

12,802

11,454

Prepaids and other assets

107,428

101,685

Total homebuilding assets

4,000,100

3,506,420


Financial Services:

Cash and cash equivalents

81,100

77,267

Mortgage loans held-for-sale, net

230,789

232,556

Other assets

70,941

48,677

Total financial services assets

382,830

358,500

Total Assets

$

4,382,930

$

3,864,920


LIABILITIES AND EQUITY


Homebuilding:

Accounts payable

$

120,496

$

98,862

Accrued and other liabilities

333,880

300,735

Revolving credit facility

10,000

10,000

Senior notes, net

1,384,475

1,037,391

Total homebuilding liabilities

1,848,851

1,446,988


Financial Services:

Accounts payable and accrued liabilities

101,725

95,630

Mortgage repurchase facility

217,482

202,390

Total financial services liabilities

319,207

298,020

Total Liabilities

2,168,058

1,745,008


Stockholders’ Equity

Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued or outstanding

Common stock, $0.01 par value; 250,000,000 shares authorized; 70,265,205 and 64,851,126 issued and outstanding at March 31, 2021 and December 31, 2020, respectively

703

649

Additional paid-in-capital

1,698,109

1,407,597

Retained earnings

516,060

711,666

Total Stockholders’ Equity

2,214,872

2,119,912

Total Liabilities and Stockholders’ Equity

$

4,382,930

$

3,864,920

 


M.D.C. HOLDINGS, INC.


Consolidated Statement of Cash Flows

(Unaudited)

Three Months Ended

March 31,

2021

2020

(Dollars in thousands)


Operating Activities:

Net income

$

110,690

$

36,760

Adjustments to reconcile net income to net cash provided by operating activities:

Stock-based compensation expense

9,926

4,440

Depreciation and amortization

7,003

5,152

Net (gain) loss on marketable equity securities

13,268

Deferred income tax expense

(1,348)

1,131

Net changes in assets and liabilities:

Trade and other receivables

(40,282)

(1,611)

Mortgage loans held-for-sale, net

1,767

63,100

Housing completed or under construction

(218,655)

(178,873)

Land and land under development

34,978

29,051

Prepaids and other assets

(23,594)

(8,460)

Accounts payable and accrued liabilities

61,558

(1,131)

Net cash used in operating activities

(57,957)

(37,173)


Investing Activities:

Purchases of marketable securities

(9,782)

Sales of marketable securities

9,276

Purchases of property and equipment

(5,749)

(6,512)

Net cash used in investing activities

(5,749)

(7,018)


Financing Activities:

Payments on mortgage repurchase facility, net

15,092

(40,872)

Repayment of senior notes

(250,000)

Proceeds from issuance of senior notes

347,725

298,050

Dividend payments

(26,665)

(20,768)

Payments of deferred financing costs

(819)

Issuance of shares under stock-based compensation programs, net

1,009

8,194

Net cash provided by (used in) financing activities

336,342

(5,396)

Net increase (decrease) in cash, cash equivalents and restricted cash

272,636

(49,587)

Cash, cash equivalents and restricted cash:

Beginning of period

503,972

474,212

End of period

$

776,608

$

424,625


Reconciliation of cash, cash equivalents and restricted cash:

Homebuilding:

Cash and cash equivalents

$

678,194

$

386,704

Restricted cash

17,314

15,762

Financial Services:

Cash and cash equivalents

81,100

22,159

Total cash, cash equivalents and restricted cash

$

776,608

$

424,625

 


New Home Deliveries

Three Months Ended March 31,

2021

2020

% Change

Homes

Home Sale

Revenues

Average

Price

Homes

Home Sale

Revenues

Average

Price

Homes

Home

Sale

Revenues

Average Price

(Dollars in thousands)

West

1,276

$

616,611

$

483.2

871

$

405,498

$

465.6

46

%

52

%

4

%

Mountain

612

324,717

530.6

435

222,858

512.3

41

%

46

%

4

%

East

290

100,530

346.7

241

68,729

285.2

20

%

46

%

22

%

Total

2,178

$

1,041,858

$

478.4

1,547

$

697,085

$

450.6

41

%

49

%

6

%

 


Net New Orders

Three Months Ended March 31,

2021

2020

% Change

Homes

Dollar

Value

Average

Price

Monthly

Absorption

Rate *

Homes

Dollar Value

Average Price

Monthly

Absorption Rate *

Homes

Dollar Value

Average Price

Monthly

Absorption

Rate

(Dollars in thousands)

West

1,775

$

904,691

$

509.7

5.80

1,382

$

655,892

$

474.6

5.13

28

%

38

%

7

%

13

%

Mountain

1,011

562,753

556.6

5.91

693

339,132

489.4

3.54

46

%

66

%

14

%

67

%

East

423

168,021

397.2

4.62

324

97,723

301.6

3.66

31

%

72

%

32

%

26

%

Total

3,209

$

1,635,465

$

509.6

5.64

2,399

$

1,092,747

$

455.5

4.33

34

%

50

%

12

%

30

%


*Calculated as total net new orders in period ÷ average active communities during period ÷ number of months in period

 


Active Subdivisions

Average Active Subdivisions

Active Subdivisions

Three Months Ended

March 31,

%

March 31,

%

2021

2020

Change

2021

2020

Change

West

97

92

5

%

102

90

13

%

Mountain

55

64

(14)

%

57

65

(12)

%

East

34

29

17

%

31

30

3

%

Total

186

185

1

%

190

185

3

%

 


Backlog

March 31,

2021

2020

% Change

Homes

Dollar

Value

Average

Price

Homes

Dollar

Value

Average

Price

Homes

Dollar

Value

Average

Price

(Dollars in thousands)

West

4,209

$

2,157,618

$

512.6

2,534

$

1,227,996

$

484.6

66

%

76

%

6

%

Mountain

2,417

$

1,355,201

560.7

1,469

$

754,155

513.4

65

%

80

%

9

%

East

1,060

$

414,474

391.0

650

$

191,972

295.3

63

%

116

%

32

%

Total

7,686

$

 

3,927,293

$

511.0

4,653

$

2,174,123

$

467.3

65

%

81

%

9

%

 


Homes Completed or Under Construction (WIP lots)

March 31,

%

2021

2020

Change

Unsold:

Completed

36

160

(78)

%

Under construction

64

216

(70)

%

Total unsold started homes

100

376

(73)

%

Sold homes under construction or completed

5,854

3,259

80

%

Model homes under construction or completed

502

502

%

Total homes completed or under construction

6,456

4,137

56

%

 


Lots Owned and Optioned (including homes completed or under construction)

March 31, 2021

March 31, 2020

Lots

Owned

Lots

Optioned

Total

Lots

Owned

Lots

Optioned

Total

Total

% Change

West

12,658

3,921

16,579

9,641

2,393

12,034

38

%

Mountain

6,790

3,418

10,208

6,540

4,007

10,547

(3)

%

East

3,088

2,148

5,236

2,410

2,133

4,543

15

%

Total

22,536

9,487

32,023

18,591

8,533

27,124

18

%

 


Selling, General and Administrative Expenses

Three Months Ended March 31,

2021

2020

Change

(Dollars in thousands)

General and administrative expenses

$

57,163

$

45,089

$

12,074


General and administrative expenses as a percentage of home sale revenues

5.5

%

6.5

%

-100 bps

Marketing expenses

$

25,703

$

21,446

$

4,257


Marketing expenses as a percentage of home sale revenues

2.5

%

3.1

%

-60 bps

Commissions expenses

$

32,127

$

22,786

$

9,341


Commissions expenses as a percentage of home sale revenues

3.1

%

3.3

%

-20 bps

Total selling, general and administrative expenses

$

114,993

$

89,321

$

25,672


Total selling, general and administrative expenses as a percentage ofhome sale revenues

11.0

%

12.8

%

-180 bps

 


Capitalized Interest

Three Months Ended

March 31,

2021

2020

(Dollars in thousands)

Homebuilding interest incurred

$

17,332

$

16,534

Less: Interest capitalized

(17,332)

(16,534)

Homebuilding interest expensed

$

$

Interest capitalized, beginning of period

$

52,777

$

55,310

Plus: Interest capitalized during period

17,332

16,534

Less: Previously capitalized interest included in home cost of sales

(14,841)

(12,767)

Interest capitalized, end of period

$

55,268

$

59,077

 

Cision View original content:http://www.prnewswire.com/news-releases/mdc-holdings-announces-first-quarter-2021-results-301279845.html

SOURCE M.D.C. Holdings, Inc.

Thermo Fisher Scientific Reports First Quarter 2021 Results

PR Newswire

WALTHAM, Mass., April 29, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021.

First Quarter 2021 Highlights

  • First quarter revenue increased 59% to $9.91 billion.
  • First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.88.
  • First quarter adjusted EPS increased 145% to $7.21.
  • Continued significant role in enabling the COVID-19 response, helping to scale vaccine production and supporting testing globally, and accelerated growth in the base business.
  • Strong start to the year in terms of product launches including two Thermo Scientific Orbitrap Exploris Gas Chromatography-Mass Spectrometers, which bring high-resolution analysis to a range of applications, including toxicology and metabolomics, the Thermo Scientific Spectra Ultra electron microscope for improved throughput and workflow in materials science applications, the Kingfisher Apex Purification System for high throughput sample preparation and the Thermo Scientific AerosolSense Sampler, an in-air surveillance solution for pathogens, including SARS-CoV-2.
  • Continued to increase our capacity to meet customer demand. In the quarter, we began shipping single use technologies from our new facility in Suzhou to bioproduction customers in China. We also brought additional capacity online in Singapore for bioproduction and at two sites in North America for laboratory plastics.
  • Advanced our environmental, social and governance priorities and committed to an impact investment of $25 million in financial institutions focused on minority communities.
  • Very active capital deployment to start the year including repurchasing $2 billion of stock, increasing our dividend by 18% and completing the acquisition of Mesa Biotech, Inc., a point-of-care molecular diagnostic company.
  • After quarter end, announced an agreement to acquire PPD, Inc., a leading global provider of clinical research services, for $17.4 billion.

Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”

“We are off to an excellent start to the year. Market conditions are strong, and our team is executing at an incredibly high level. From a financial perspective, we again delivered exceptional growth in revenue, earnings and free cash flow for the quarter,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We began accelerating our investments in talent, capabilities and capacity in the second half of 2020 and we are already starting to see the benefits of those actions which will ensure an even brighter future for our company.”

Casper added, “I am also very excited about our recently announced agreement to acquire PPD, Inc. This is a great fit for our company and will strengthen our value proposition for our largest and fastest growing end market, provide exciting career opportunities for our colleagues, and create significant shareholder value.”

First Quarter 2021

Revenue for the quarter grew 59% to $9.91 billion in 2021, versus $6.23 billion in 2020. Organic revenue growth was 53%; acquisitions increased revenue by 2% and currency translation increased revenue by 4%.

GAAP Earnings Results

GAAP diluted EPS in the first quarter of 2021 increased 198% to $5.88, versus $1.97 in the same quarter last year. GAAP operating income for the first quarter of 2021 was $3.05 billion, compared with $0.91 billion in the year-ago quarter. GAAP operating margin was 30.8%, compared with 14.5% in the first quarter of 2020.

Non-GAAP Earnings Results

Adjusted EPS in the first quarter of 2021 increased 145% to $7.21, versus $2.94 in the first quarter of 2020. Adjusted operating income for the first quarter of 2021 grew 155% compared with the year-ago quarter. Adjusted operating margin was 35.4%, compared with 22.1% in the first quarter of 2020.

Annual Guidance for 2021

The company will provide updates on its 2021 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern time.

Segment Results

Management uses adjusted operating results to monitor and evaluate performance of the company’s four business segments, as highlighted below. Since these results are used for this purpose, they are also considered to be prepared in accordance with GAAP.

Life Sciences Solutions Segment

Life Sciences Solutions Segment revenue grew 137% to $4.20 billion in the first quarter of 2021, compared with revenue of $1.77 billion in the first quarter of 2020. Segment adjusted operating margin was 54.2%, versus 38.0% in the 2020 quarter.

Analytical Instruments Segment

Analytical Instruments Segment revenue grew 26% to $1.39 billion in the first quarter of 2021, compared with revenue of $1.10 billion in the first quarter of 2020. Segment adjusted operating margin was 19.6%, versus 15.5% in the 2020 quarter.

Specialty Diagnostics Segment

Specialty Diagnostics Segment revenue grew 69% to $1.62 billion in the first quarter of 2021, compared with revenue of $0.96 billion in the first quarter of 2020. Segment adjusted operating margin was 26.5%, versus 24.7% in the 2020 quarter.

Laboratory Products and Services Segment

Laboratory Products and Services Segment revenue grew 32% to $3.60 billion in the first quarter of 2021, compared with revenue of $2.73 billion in the first quarter of 2020. Segment adjusted operating margin was 14.8%, versus 10.8% in the 2020 quarter.

Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS, adjusted operating income and adjusted operating margin, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and the impact of significant tax audits or events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We also use a non-GAAP measure, free cash flow, which is operating cash flow, excluding net capital expenditures to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts.

For example:

We exclude costs and tax effects associated with restructuring activities, such as reducing overhead and consolidating facilities. We believe that the costs related to these restructuring activities are not indicative of our normal operating costs.

We exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs. We exclude these costs because we do not believe they are indicative of our normal operating costs.

We exclude the expense and tax effects associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of 3 to 20 years. Based on acquisitions closed through the end of the first quarter of 2021, adjusted EPS will exclude approximately $3.45 of expense for the amortization of acquisition-related intangible assets. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

We also exclude certain gains/losses and related tax effects, the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate changes), which are either isolated or cannot be expected to occur again with any predictability and that we believe are not indicative of our normal operating gains and losses. For example, we exclude gains/losses from items such as the sale of a business or real estate, gains or losses on significant litigation-related matters, gains on curtailments of pension plans and the early retirement of debt.

We also report free cash flow, which is operating cash flow, excluding net capital expenditures to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities.

Thermo Fisher’s management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring the company’s core operating performance and comparing such performance to that of prior periods and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes.

The non-GAAP financial measures of Thermo Fisher’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying tables. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher’s results computed in accordance with GAAP.

Conference Call

Thermo Fisher Scientific will hold its earnings conference call today, April 29, 2021, at 8:30 a.m. Eastern time. To listen, dial (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. The conference ID is 7956359. You may also listen to the call live on our website, www.thermofisher.com, by clicking on “Investors.” You will find this press release, including the accompanying reconciliation of non-GAAP financial measures and related information, in that section of our website under “Financial Results.” An audio archive of the call will be available under “Webcasts and Presentations” through Friday, May 14, 2021.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our pending acquisition of PPD, Inc., may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

 


Condensed Consolidated Statement of Income (unaudited) (a)(b)

Three Months Ended

April 3,

% of

March 28,

% of

(In millions except per share amounts)

2021

Revenues

2020

Revenues

Revenues

$

9,906

$

6,230

Costs and Operating Expenses:

Cost of revenues (c)

4,557

46.0

%

3,365

54.0

%

Selling, general and administrative expenses (d)

1,543

15.6

%

1,251

20.1

%

Amortization of acquisition-related intangible assets

423

4.3

%

425

6.8

%

Research and development expenses

320

3.2

%

245

3.9

%

Restructuring and other costs (e)

14

0.1

%

38

0.6

%

6,857

69.2

%

5,324

85.5

%

Operating Income

3,049

30.8

%

906

14.5

%

Interest Income

12

36

Interest Expense

(125)

(126)

Other (Expense) Income (f)

(183)

12

Income Before Income Taxes

2,753

828

Provision for Income Taxes (g)

(416)

(40)

Net Income

$

2,337

23.6

%

$

788

12.6

%

Earnings per Share:

Basic

$

5.93

$

1.99

Diluted

$

5.88

$

1.97

Weighted Average Shares:

Basic

394

397

Diluted

397

400


Reconciliation of Adjusted Operating Income and Adjusted Operating Margin

GAAP Operating Income (a)

$

3,049

30.8

%

$

906

14.5

%

Cost of Revenues Charges (c)

8

0.1

%

2

0.1

%

Selling, General and Administrative Charges (d)

16

0.1

%

6

0.1

%

Restructuring and Other Costs (e)

14

0.1

%

38

0.6

%

Amortization of Acquisition-related Intangible Assets

423

4.3

%

425

6.8

%

Adjusted Operating Income (b)

$

3,510

35.4

%

$

1,377

22.1

%


Reconciliation of Adjusted Net Income

GAAP Net Income (a)

$

2,337

$

788

Cost of Revenues Charges (c)

8

2

Selling, General and Administrative Charges (d)

16

6

Restructuring and Other Costs (e)

14

38

Amortization of Acquisition-related Intangible Assets

423

425

Other Expense (Income) (f)

197

14

Benefit from Income Taxes (g)

(130)

(98)

Adjusted Net Income (b)

$

2,865

$

1,175


Reconciliation of Adjusted Earnings per Share

GAAP Diluted EPS (a)

$

5.88

$

1.97

Cost of Revenues Charges, Net of Tax (c)

0.01

0.01

Selling, General and Administrative Charges, Net of Tax (d)

0.03

0.01

Restructuring and Other Costs, Net of Tax (e)

0.03

0.07

Amortization of Acquisition-related Intangible Assets, Net of Tax

0.84

0.83

Other Expense (Income), Net of Tax (f)

0.43

0.03

(Benefit from) Provision for Income Taxes (g)

(0.01)

0.02

Adjusted EPS (b)

$

7.21

$

2.94


Reconciliation of Free Cash Flow

GAAP Net Cash Provided by Operating Activities (a)

$

1,978

$

356

Purchases of Property, Plant and Equipment

(628)

(253)

Proceeds from Sale of Property, Plant and Equipment

5

4

Free Cash Flow

$

1,355

$

107

 


Segment Data

Three Months Ended

April 3,

% of

March 28,

% of

(In millions)

2021

Revenues

2020

Revenues


Revenues

Life Sciences Solutions

$

4,203

42.4

%

$

1,774

28.5

%

Analytical Instruments

1,387

14.0

%

1,101

17.7

%

Specialty Diagnostics

1,615

16.3

%

958

15.4

%

Laboratory Products and Services

3,597

36.3

%

2,730

43.8

%

Eliminations

(896)

-9.0

%

(333)

-5.4

%

Consolidated Revenues

$

9,906

100.0

%

$

6,230

100.0

%


Operating Income and Operating Margin

Life Sciences Solutions

$

2,279

54.2

%

$

675

38.0

%

Analytical Instruments

272

19.6

%

171

15.5

%

Specialty Diagnostics

428

26.5

%

236

24.7

%

Laboratory Products and Services

531

14.8

%

295

10.8

%

Subtotal Reportable Segments

3,510

35.4

%

1,377

22.1

%

Cost of Revenues Charges (c)

(8)

-0.1

%

(2)

-0.1

%

Selling, General and Administrative Charges (d)

(16)

-0.1

%

(6)

-0.1

%

Restructuring and Other Costs (e)

(14)

-0.1

%

(38)

-0.6

%

Amortization of Acquisition-related Intangible Assets

(423)

-4.3

%

(425)

-6.8

%

GAAP Operating Income (a)

$

3,049

30.8

%

$

906

14.5

%

(a) “GAAP” (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP).

(b) Adjusted results are non-GAAP measures and, for income measures, exclude certain charges to cost of revenues (see note (c) for details); certain credits/charges to selling, general and administrative expenses (see note (d) for details); amortization of acquisition-related intangible assets; restructuring and other costs (see note (e) for details); certain other gains or losses that are either isolated or cannot be expected to occur again with any predictability (see note (f) for details); and the tax consequences of the preceding items and certain other tax items (see note (g) for details).

(c) Reported results in 2021 include charges for the sale of inventories revalued at the date of acquisition. Reported results in 2020 include charges to conform the accounting policies of a recently acquired business with the company’s accounting policies.

(d) Reported results in 2021 and 2020 include certain third-party expenses, principally transaction/integration costs related to recent/terminated acquisitions. Reported results in 2021 also include $2 of charges for changes in estimates of contingent acquisition consideration.

(e) Reported results in 2021 and 2020 include restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in 2021 also include $13 of charges for compensation contractually due to employees of acquired businesses at the date of acquisition.

(f) Reported results in 2021 include $197 of losses on the early extinguishment of debt. Reported results in 2020 include $17 of costs for a subsequently terminated acquisition, primarily for entering hedging contracts and amortization of bridge loan commitments fees; and $1 of net charges for the settlement/curtailment of pension plans, offset in part by $4 of gains from investments.

(g) Reported provision for income taxes in 2021 and 2020 includes incremental tax benefit for the pre-tax reconciling items between GAAP and adjusted net income and $4 and $(6) of incremental tax benefit (provision), respectively, from adjusting the company’s non-U.S. deferred tax balances as a result of tax rate changes.

Notes:

Consolidated depreciation expense is $198 and $149 in 2021 and 2020, respectively.

 


Condensed Consolidated Balance Sheet (unaudited)

April 3,

December 31,

(In millions)

2021

2020

Assets

Current Assets:

Cash and cash equivalents

$

5,583

$

10,325

Accounts receivable, net

5,554

5,741

Inventories

4,342

4,029

Other current assets

2,206

1,862

Total current assets

17,685

21,957

Property, Plant and Equipment, Net

6,133

5,912

Acquisition-related Intangible Assets, Net

12,831

12,685

Other Assets

2,459

2,457

Goodwill

26,823

26,041

Total Assets

$

65,931

$

69,052

Liabilities and Shareholders’ Equity

Current Liabilities:

Short-term obligations and current maturities of long-term obligations

$

4

$

2,628

Other current liabilities

6,991

7,676

Total current liabilities

6,995

10,304

Other Long-term Liabilities

5,237

5,134

Long-term Obligations

18,641

19,107

Total Shareholders’ Equity

35,058

34,507

Total Liabilities and Shareholders’ Equity

$

65,931

$

69,052


Condensed Consolidated Statement of Cash Flows (unaudited)

Three Months Ended

April 3,

March 28,

(In millions)

2021

2020


Operating Activities

Net income

$

2,337

$

788

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

621

574

Change in deferred income taxes

24

(41)

Other non-cash expenses, net

317

110

Changes in assets and liabilities, excluding the effects of acquisitions and disposition

(1,321)

(1,075)

Net cash provided by operating activities

1,978

356


Investing Activities

Acquisitions, net of cash acquired

(1,343)

(4)

Purchases of property, plant and equipment

(628)

(253)

Proceeds from sale of property, plant and equipment

5

4

Other investing activities, net

(32)

(7)

Net cash used in investing activities

(1,998)

(260)


Financing Activities

Net proceeds from issuance of debt

2,185

Repayment of debt

(2,804)

(1)

Net proceeds from issuance of commercial paper

382

Repayment of commercial paper

(321)

Purchases of company common stock

(2,000)

(1,500)

Dividends paid

(87)

(76)

Net proceeds from issuance of company common stock under employee stock plans

20

48

Other financing activities, net

21

(98)

Net cash (used in) provided by financing activities

(4,850)

619

Exchange Rate Effect on Cash

137

(127)

(Decrease) Increase in Cash, Cash Equivalents and Restricted Cash

(4,733)

588

Cash, Cash Equivalents and Restricted Cash at Beginning of Period

10,336

2,422

Cash, Cash Equivalents and Restricted Cash at End of Period

$

5,603

$

3,010

Free Cash Flow (a)

$

1,355

$

107

(a) Free cash flow is net cash provided by operating activities less net purchases of property, plant and equipment.

 

Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: [email protected]

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-reports-first-quarter-2021-results-301279550.html

SOURCE Thermo Fisher Scientific